2024 Nasdaq rxrx - See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

 
Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.. Nasdaq rxrx

EXIT - Nasdaq: RXRX. Follow us on twitter · Follow us on linkedin · Follow us on facebook. Using its digital biology platform, Recursion is building a pipeline ...Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) At close: 04:00PM EST 6.65... Nov 27, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This will be used […] Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.The Dow Jones Industrial Average paced gains with a jump of nearly 1.5%, or more than 500 points, reaching a new closing high for 2023. The S&P 500 popped nearly 0.4%, reversing earlier losses ...At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.DocuSign (NASDAQ: DOCU) ... SDGR), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Amongst these choices, I would favor AbCellera Biologics in the current environment, ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.45%) on July 12, Recursion Pharmaceuticals ( RXRX 10.49%) saw its stock blast off, rising 87% over the following ...Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ...At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...The average trading volume for RXRX on November 13, 2023 was 3.54M shares. RXRX) stock’s latest price update. Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone rise by 0.37 in comparison to its previous close of 5.46, however, the company has experienced a -0.90% decrease in its stock price over the last five trading days.Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer.At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time …If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both ...For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After …Benzinga. Apr. 25, 2021, 10:33 PM. Cathie Wood-led Ark Investment Management on Friday snapped up another 221,167 shares of the cryptocurrency exchange Coinbase Global Inc (NASDAQ:COIN) worth ...Cathie Wood can't get enough of Recursion Pharmaceuticals (NASDAQ: RXRX) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in ...Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...3 min read. ·. Jun 7, 2022. 2. Today we’re announcing the raise of two new Obvious funds, which combine to $461M of new capital: 4 We’ve completed the fundraise for our fourth flagship early ...Nov 22, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ... 24. Walkme Ltd (NASDAQ:WKME) SaaS company WalkMe is one of the stocks with negative beta. The company in August posted second quarter results. Adjusted EPS in the quarter came in at $0.00 beating ...Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time …Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AMFind the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.15 Kas 2023 ... Graphic designer/iStock via Getty Images. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday ...Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ... Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest …Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...November 16, 2023 at 10:06 PM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ... Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative ...Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not …Shares of Recursion Pharmaceuticals (RXRX 4.89%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in …MarketWatch IBD Sign In Recursion Pharmaceuticals Inc. RXRX (U.S.: Nasdaq) Overview News Recursion Pharmaceuticals Inc. No significant news for in the …Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Sporting 7.88% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 12/01/23 when the RXRX stock price touched $7.39 or saw a rise of 5.26%.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -2.84%). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ... 2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.RXRX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both ...SALT LAKE CITY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ...30 Haz 2021 ... ... (Nasdaq: ABCL), Recursion Pharmaceuticals (Nasdaq: RXRX), Zymergen (Nasdaq: ZY), Desktop Metal (NYSE: DM) and Lucira Health (Nasdaq: LHDX).SALT LAKE CITY, June 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full ...SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time …Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Nasdaq rxrx

Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.. Nasdaq rxrx

nasdaq rxrx

(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Founded in 2013, Recursion Pharmaceuticals is a Utah-based clinical stage "digital biotech", possessing a sophisticated robotized biology experimentation drug discovery platform, utilizing machine learning technologies, including high-throughput imaging analytics and high content …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Recursion Pharmaceuticals Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for RXRX in the last 3 months.That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention.Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at …Recursion Pharmaceuticals (NASDAQ:RXRX) recently gapped higher after receiving a $50 million investment from AI powerhouse Nvidia (NASDAQ:NVDA).With that, Recursion will use NVDA technology to ...Nov 8, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ... (NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock is the talk of Wall Street lately.Indeed, RXRX soared more than 120% Wednesday after Nvidia (NASDAQ:NVDA) announced it would invest $50 million into ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023.The analyst firm set a price target for 10.00 expecting RXRX to rise ...NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ...View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023.The analyst firm set a price target for 10.00 expecting RXRX to rise ...SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and …Salt Lake City, March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced ...On July 21, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported that the European Commission has authorized an orphan drug designation to its inhibitor REC-4881 for the treatment of familial ...2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) At close: 04:00PM EST 6.65... Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021. Skip to main content. Skip to main menu; Skip to user menu; Login |Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Jul 13, 2023 · In recent trading, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) have crossed above the average analyst 12-month target price of $11.29, changing hands for $12.02/share. When a stock ... SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.Sep 5, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ...2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.12 Nis 2023 ... investments in companies including Recursion (NASDAQ: RXRX), which uses automation and deep learning to develop novel therapeutics; Enveda ...View real-time RXRX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Stock Exchange NASDAQ Ticker Symbol RXRX Full Company Profile Financial Performance In 2022, RXRX's revenue was $39.84 million, an increase of …Jul 12, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... 22 Kas 2023 ... That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...Nov 22, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ... Jan 12, 2022 · So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ... Recursion Pharmaceuticals (NASDAQ:RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. View real-time RXRX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...The Dow Jones Industrial Average paced gains with a jump of nearly 1.5%, or more than 500 points, reaching a new closing high for 2023. The S&P 500 popped nearly 0.4%, reversing earlier losses ...#3 Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Sector: Healthcare | Biotechnology. Reason: Falling Wedge Pattern Breakout. A falling wedge pattern is formed by joining two downward-sloping, converging trendlines having a contracting range. The pattern appears to be wide at the top and continues to contract as prices fall.Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,5 Eki 2023 ... The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share.. S stock news